CA-SYSDIG
13.1.2022 17:56:06 CET | Business Wire | Press release
Sysdig, Inc., the unified container and cloud security leader, today announced that Gerald Combs, the Wireshark creator and project leader, has joined the company. Wireshark, an open source tool, is the world’s foremost and widely-used traffic protocol analyzer with more than 60 million downloads in the last 5 years, an average of one million per month. Loris Degioanni, CTO and Founder of Sysdig, partnered with Gerald to launch Wireshark more than 15 years ago. Gerald joins Sysdig’s open source team, which is a significant contributor to many open source projects, including Falco, eBPF, Sysdig open source, Sysdig Inspect, and other tools and libraries. With Gerald joining, Sysdig assumes responsibility for sponsoring and managing the Wireshark community and extending Wireshark’s use cases to the cloud ecosystem.
Wireshark is an open source GUI network package capturing tool that enables teams to monitor network traffic, learn protocols and packet basics, and troubleshoot network problems. For network admins, Wireshark is the de facto standard for checking health and security at a microscopic level. Wireshark takes packet captures and saves them for later viewing. Teams can filter through that traffic to find evidence from an incident. With more than 1,900 contributors, the number of integrations continues to expand. Adoption is broad as Wireshark can be used consistently across nearly any environment, including Windows, Linux, and macOS, among others.
“It’s amazing to see the lasting heritage of Wireshark, led by Gerald. You can guarantee most of the Fortune 2000 are actively using Wireshark,” said Loris Degioanni, CTO and Founder, Sysdig. “I am excited to be reunited with Gerald and to advance the project in the same way Sysdig supports Falco and the Sysdig open source project. This move ensures Wireshark will continue to innovate. Our goal at Sysdig is to empower Wireshark.”
The Importance of Healthy Open Source Projects
The Log4j and OpenSSL vulnerabilities have shown that large and small organizations rely on open source projects and major issues arise when critical vulnerabilities are found in these tools. Log4j spotlighted the importance of maintaining open source projects. Continuing to maintain the project’s health is of the utmost importance considering the widespread adoption of Wireshark.
The Wireshark Story
While studying network analyzers and creating a popular open source tool while working on his PhD in Italy, Loris was invited to the United States to do research on packets, which is where he met Gerald. Gerald joined Loris at CACE Technologies in the early 2000’s, where they collaborated and grew Wireshark. CACE Technologies was later acquired and since that time, Gerald has focused on growing the tool and ensuring Wireshark and its community have the resources needed to thrive.
“I am excited to be reunited with Loris and explore the opportunity we have to expand Wireshark to the cloud,” said Gerald Combs, Director of Open Source Projects, Sysdig. “My move to Sysdig and the subsequent move for Wireshark will give Wireshark the corporate sponsor it needs to continue moving forward. This is a significant milestone for Wireshark and with Sysdig’s backing, we will have the assistance we need to continue to evolve use cases for Wireshark.”
The Wireshark Future
Sysdig will ensure the community has the backing it needs, including supporting Gerald as the leader of the community, ensuring Wireshark has the resources needed to operate, and sponsoring SharkFest. Sysdig has an open source team that will contribute to Wireshark. Reunited, Gerald and Loris will investigate new innovative ways to address challenges with securing the cloud.
Sysdig’s Commitment to Open Source
Sysdig was founded as an open source company and the Sysdig platform was built on an open source foundation to address the security challenges of modern cloud applications. Open source Sysdig and Falco are projects that were created by Sysdig to leverage deep visibility as a foundation for security, and they have become standards for container and cloud threat detection and incident response. Falco, which was contributed to the CNCF in 2018, is now an incubation-level hosted project with more than 40 million downloads.
Resources
- Read Loris’ blog: Sysdig Welcomes Gerald and the Wireshark Community .
- Read Gerald's blog: We Have a New Sponsor .
- Visit Wireshark.org .
- Visit Sysdig.com .
About Sysdig
Sysdig is driving the standard for securing the cloud, empowering organizations to confidently secure containers, Kubernetes, and cloud services. The Sysdig platform enables teams to secure the build, detect and respond to runtime threats, and continuously manage cloud configurations, permissions and compliance. Sysdig is a SaaS platform built on an open source stack that includes Falco and Sysdig open source, the open standards for runtime threat detection and response. The largest and most security conscious companies rely on Sysdig for container and cloud security. sysdig.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005266/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
